

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 February 2023 (09.02.2023)



(10) International Publication Number
WO 2023/014296 A3

(51) International Patent Classification:

A61K 31/17 (2006.01) *A61K 31/423* (2006.01)
A61K 31/165 (2006.01) *A61K 31/428* (2006.01)
A61K 31/416 (2006.01) *A61K 31/357* (2006.01)
A61K 31/4162 (2006.01) *A61K 31/433* (2006.01)
A61K 31/4188 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/SG2022/050551

(22) International Filing Date:

02 August 2022 (02.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/228,240 02 August 2021 (02.08.2021) US

(71) Applicants: **NATIONAL UNIVERSITY OF SINGAPORE** [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG). **BETH ISRAEL DEACONESS MEDICAL CENTER, INC.** [US/US]; 330 Brookline Avenue, Boston, Massachusetts 02215 (US).

(72) Inventors: **VU, Le Kim Anh**; c/o National University of Singapore, Cancer Science Institute of Singapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **LIU, Bee Hui**; c/o National University of Singapore, Cancer Science Institute of Singapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **TENEN, Daniel Geoffrey**; c/o National University of Singapore, Cancer Science Institute of Singapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG).

(74) Agent: **KINNAIRD, James Welsh**; Marks & Clerk Singapore LLP, Tanjong Pagar Post Office, P.O. Box 636, Singapore 910816 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))


Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

27 April 2023 (27.04.2023)

(54) Title: MOLECULAR GLUE AND SALL4 DEGRADER



I

(57) Abstract: Provided is the use of compounds of Formula I, as well as certain specific compounds, or a pharmaceutically acceptable salt, solvate or derivative thereof, in the preparation of a medicament to treat cancer, such as liver cancer (e.g. hepatocellular carcinoma) and lung cancer.

WO 2023/014296 A3